On the Increase in Use of GLP-1s
US$ 21.89
glp-1 for mash A New Phase in Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist) Resmetirom and GLP-1 agonists for
Description
Insurance Coverage Note: HealthRX states it is not enrolled in Medicare or Medicaid and does not accept commercial insurance
The figure below captures this central tension: payers are almost evenly split in their perspectives on treatment of obesity, with some regarding pharmaceutical coverage for obesity as a response to a chronic medical condition, while others see it more as addressing a lifestyle issue
Real Care
R.MohammedI.BsheshK.MareiI.YeK.DingH.et al (2022)
No rotating cast of providers you will never see again
